THE INTRADAY

ABT · Company KPIs

Abbott (ABT) KPIs

Established Pharmaceuticals Key Emerging Markets comparable sales growth. As reported in SEC filings, with the source line for each figure.

Established Pharmaceuticals Key Emerging Markets comparable sales growth

10.9% for the period ended Sep 30, 2026

Sep 30, 2025: 11.1%Dec 31, 2025: 8.7%Mar 31, 2026: 9.4%Jun 30, 2026: 10.7%Sep 30, 2026: 10.9%Sep 30, 2025Sep 30, 2026

The filings read for this page do not define this measure.

Established Pharmaceuticals Key Emerging Markets comparable sales growth, as first reported, with the line it was read from
Period endedFigureFiling text
Sep 30, 202610.9%Comparable sales growth · 8.4 · 10.9 · 1.68-K filed 2026-10-21
Jun 30, 202610.7%Sales in these geographies increased 9.8 percent on a reported basis and 10.7 percent on a comparable basis, led by double-digit growth in several countries across the Latin America and Asia Pacific regions.8-K filed 2026-07-16
Mar 31, 20269.4%Comparable sales growth · 9.0 · 9.4 · 7.98-K filed 2026-04-16
Dec 31, 20258.7%Organic · 7.0 · 8.7 · 1.98-K filed 2026-01-22
Sep 30, 202511.1%Organic · 7.1 · 11.1 · (2.5)8-K filed 2025-10-15

Reading notes

Figures are shown as first reported. If a later filing prints a different figure for the same period, both appear. A figure marked ≈ or shown in words is how the company itself states it, not an estimate of ours. Companies change definitions over time, so compare periods with the quoted definition in mind. Periods that failed our checks are left out, so gaps are expected.